FDA Approves Sacituzumab Govitecan Plus Pembrolizumab for First-Line PD-L1–Positive TNBC
Jun 25, 2026
View online
FDA Approves Sacituzumab Govitecan Plus Pembrolizumab for First-Line PD-L1–Positive TNBC
Nature Medicine Retracts NSCLC Immunochemotherapy Trial: 6 Serious Concerns Explained
Anthony Letai: Excited to See the NIH Office of Research Innovation, Validation, and Application Launch
Michael May: Already Giving Patients Daraxonrasib Off Trial Only 21 Days After the Practice-changing Results
Natera Celebrates Major Milestones for Signatera in Bladder and Colorectal Cancer
EORTC Announces 2027 Summit for Clinical Cancer Research in Brussels
EU-REST Project Highlights Urgent Need for Dedicated RTT Education and Workforce Planning
25 Posts Not To Miss from MASCC 2026
Global Ovarian Cancer Research Consortium AI Accelerator Grant — OCRA
ACOG Foundation 2026 Request for Grant Proposals
21st MRS Biennial Congress
Global AYA ALL Status – Resonance
The Voice of Oncology
Unsubscribe
|
Manage subscription
OncoDaily, P53 Inc.
867 Boylston Street, 5th Floor, Suite 1094, Boston, MA 02116
Copyright (C) 2023-2026. OncoDaily, P53 Inc. All rights reserved.
